Navigation Links
Champions Oncology Reports Full Year 2011 Financial Results
Date:7/15/2011

eaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2011 for a discussion of such risks, uncertainties and other factors.  Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law. Champions Oncology, Inc.

Reconciliation of GAAP to Non-GAAP Net IncomeFiscal Year Ended

April  30,20112010Net loss attributable to Champions – GAAP($3,802,000)($2,923,000)Less:Stock-based compensation3,133,000593,000Net loss attributable to Champions-non-GAAP:($669,000)($2,330,000)Net income (loss) per common share attributable to Champions – GAAPBasic and diluted

Less:

Stock-based compensation per common share attributable to

Champions – non GAAP:($0.10)($0.09)Net income (loss) per common share attributable to Champions– non GAAP:  $0.08$0.02Basic and diluted($0.02)

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
2. Champions Biotechnology Changes Name to Champions Oncology
3. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
4. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
5. Champions Biotechnology Reports Additions to its Management Team
6. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
7. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
8. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
9. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
10. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
11. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Philadelphia’s newest entrepreneurial incubation space ... their start. The Innovation Center @3401 , a collaborative ... City Science Center to help attract and nurture start-up ... July 28. , The Innovation Center @3401 ... Market Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... SILVER SPRING, Md., July 29, 2014  United ... today announced its financial results for the ... "Our continued growth shows that our medicines ... from pulmonary arterial hypertension (PAH)," said Martine ... Executive Officer. "The commercial launch this quarter ...
(Date:7/29/2014)... Dr. Jason Wendel – recipient of a ... of the Top 10 Plastic Surgeon Specialists for Nashville, TN ... His complete line includes a Hydration Booster, Retexturing Night Crème, ... and skin a younger, more radiant appearance while protecting them ... different, that is why at Dr. J. J. Wendel Plastic ...
(Date:7/28/2014)... , July 28, 2014 Sapphire Energy, ... today announced the appointment of biotechnology veteran James ... board of directors. Levine replaces Cynthia ,CJ, Warner, who ... will remain chairman of the company,s board of directors. ... Energy,s mission to deliver commercial scale algae-based fuels has ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... When semiconductor nanorods are exposed to light, ... clustering nanorods together, physicists at the University of ... is increased dramatically providing new insight into this ... by associate professor Marija Drndic,s group, including graduate ...
... June 23, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (" China-Biotics ... (NASDAQ: CHBT ), a leading developer, manufacturer, and ... 20, 2011, the Company received a letter from the NASDAQ Listing ... Company has not yet filed its Annual Report on Form 10-K ...
... Biosciences, Inc. (NASDAQ: NBIX ) announced today that ... a Notice of Allowance for the Company,s proprietary Vesicular Monoamine ... that a composition of matter patent on NBI-98854 will have ... Additionally, on June 17, 2011, the Company held a ...
Cached Biology Technology:Penn physicists observe 'campfire effect' in blinking nanorod semiconductors 2Penn physicists observe 'campfire effect' in blinking nanorod semiconductors 3China-Biotics, Inc. Receives NASDAQ Delisting Notification 2China-Biotics, Inc. Receives NASDAQ Delisting Notification 3Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor 2Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor 3
(Date:7/29/2014)... you,ve ever ordered the wrong food at a restaurant, don,t ... have less to do with what you want and more ... analyzing 217 menus and the selections of over 300 diners, ... Journal of Hospitality Management showed that when it comes ... what you see on the menu and how you imagine ...
(Date:7/29/2014)... of Ascension Island, one of the world,s largest green ... Writing in the journal Biodiversity and Conservation , ... Government Conservation Department report that the number of green ... increased by more than 500 per cent since records ... are now estimated to be laid on the Island,s ...
(Date:7/29/2014)... of Kent has shown for the first time how ... that could have a major impact on cancer therapy ... uncovered the mechanism whereby the physical properties of the ... are ,fine-tuned, to undertake different functions. , While ... providing a framework for the cell, others are more ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2
... CA July 12, 2012 Readers of the top-ranked scientific ... noticed a recent wave of articles, most recently in the ... importance for biology and medicine. These papers, all published this ... of Professor Raymond Stevens, illuminate a large and medically important ...
... century ago, the South Pole was one of Earth,s last ... activity. Led by Monash University,s Professor Steven Chown, a ... out the current and future conservation challenges facing the Antarctic ... . The team analysed the effectiveness of the existing ...
... trying to control the invasive tamarisk plant have been ... a rapidly evolving beetle that has been changing its ... Their findings, in a paper titled "Evolution of critical ... Diorhabda carinulata , a biological control agent against ...
Cached Biology News:Large, medically important class of proteins starts to yield its secrets 2Large, medically important class of proteins starts to yield its secrets 3Large, medically important class of proteins starts to yield its secrets 4Large, medically important class of proteins starts to yield its secrets 5Large, medically important class of proteins starts to yield its secrets 6Large, medically important class of proteins starts to yield its secrets 7The challenges facing the vulnerable Antarctic 2Tamarisk biocontrol efforts get evolutionary boost 2Tamarisk biocontrol efforts get evolutionary boost 3
... Flat bottoms,• Nonreversible ... to reduce contamination,• Individual ... identification,• Uniform footprint for ... for optimal cell attachment,• ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
Biology Products: